Expressing support for the designation of July 16, 2025, as "Glioblastoma Awareness Day".
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill creates supports designating Glioblastoma Awareness Day, honors those affected by glioblastoma, recognizes the importance of biomarker testing, and encourages continued research investments including through. The main policy areas are Healthcare and Government.
Who Benefits and How
Glioblastoma patients and families would be affected, Glioblastoma Therapeutics Network would be affected, and Brain tumor research organizations would be affected.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Creates supports designating Glioblastoma Awareness Day, honors those affected by glioblastoma, recognizes the importance of biomarker testing, and encourages continued research investments including through...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates supports designating Glioblastoma Awareness Day, honors those affected by glioblastoma, recognizes the importance of biomarker testing, and encourages continued research investments including through.
Key Policy Areas
Healthcare, Government
Primary Purpose
The bill creates supports designating Glioblastoma Awareness Day, honors those affected by glioblastoma, recognizes the importance of biomarker testing, and encourages continued research investments including through.
Policy Domains
Whole bill
Identified Gains
- Glioblastoma patients and families
- Glioblastoma Therapeutics Network
- Brain tumor research organizations
Sponsors
Legislative Progress
In CommitteeMr. Williams of Texas (for himself, Mr. Mast, Ms. Schakowsky, …
Referred to the House Committee on Energy and Commerce.
Submitted in House
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Brain tumor research organizations, Glioblastoma Therapeutics Network
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology